Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.30 USD
0.00 (0.00%)
Updated Aug 29, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum F VGM
Income Statements
Fiscal Year end for Galena Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 8 | 2 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 7 | 2 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 43 | 33 | 19 | 20 |
Income After Depreciation & Amortization | -38 | -42 | -25 | -17 | -20 |
Non-Operating Income | 1 | 1 | 4 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -37 | -41 | -21 | -17 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -41 | -21 | -17 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -41 | -21 | -17 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -32 | -24 | -17 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 10 | 1 | 0 | 3 |
Income After Depreciation & Amortization | -38 | -42 | -25 | -17 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.78 | 19.40 | 15.48 | 7.98 | 2.56 |
Diluted EPS Before Non-Recurring Items | -1.34 | -2.13 | -1.34 | -2.11 | -10.84 |
Diluted Net EPS (GAAP) | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 |
Fiscal Year end for Galena Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.63 | 9.64 | 8.18 | 9.36 | 9.05 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.63 | -9.64 | -8.18 | -9.36 | -9.05 |
Non-Operating Income | 0.15 | 0.08 | 0.04 | 0.09 | 0.21 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.47 | -9.57 | -8.14 | -9.27 | -8.84 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.47 | -9.57 | -8.14 | -9.27 | -8.84 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.47 | -9.57 | -8.14 | -9.27 | -8.84 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 57.63 | 44.81 | 32.12 | 28.36 | 28.35 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.21 | -0.25 | -0.33 | -0.31 |
Diluted Net EPS (GAAP) | -0.13 | -0.21 | -0.23 | -0.33 | -0.31 |